Rejuvenate Bio
Latest round
- Series B
Last raised
- Jun 2026
Total raised
- $34M
Investors
- 8
About Rejuvenate Bio
Rejuvenate Bio Inc. is a biotechnology company focused on pioneering gene therapy solutions to combat chronic, age-related diseases, enhancing health and quality of life through advanced genetic editing technologies. Founded in 2019 by Daniel Oliver and Noah Davidsohn, Rejuvenate Bio Inc. is headquartered in San Diego, US. The company specializes in innovative gene therapy targeting chronic diseases. In June 2026, Rejuvenate Bio Inc. Rejuvenate Bio specializes in innovative gene therapy solutions aimed at addressing chronic, age-related diseases that affect a significant portion of the American population. Their core offerings encompass various human and animal health therapies designed to target the underlying genetic causes of these conditions. The company employs advanced gene editing technologies to develop therapies that not only alleviate symptoms but also aim for long-term health improvements, thereby enhancing the quality of life for individuals suffering from chronic diseases. These products are particularly relevant for healthcare providers seeking effective treatments for patients diagnosed with conditions such as diabetes and cardiovascular diseases. Rejuvenate Bio's products are marketed primarily within the United States, with potential expansion into international markets as the company grows. Rejuvenate Bio generates revenue through a combination of partnerships and direct sales of its gene therapy products. The company's revenue model includes engaging with healthcare providers and institutions that incorporate its therapies into their treatment protocols. Transactions typically involve negotiated contracts that outline specific pricing structures for different treatment regimens. The company's flagship products, which are designed to deliver targeted gene therapies, are sold on a per-treatment basis, creating a direct-to-consumer approach as well as B2B transactions with healthcare providers. This dual approach allows Rejuvenate Bio to cater to both individual patients seeking innovative treatments and larger healthcare systems looking to enhance their therapeutic offerings.
Who invested in Rejuvenate Bio
8 investors across 2 rounds
See all investors in Rejuvenate Bio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Rejuvenate Bio
Who invested in Rejuvenate Bio?
Rejuvenate Bio has 8 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Rejuvenate Bio raised?
Rejuvenate Bio has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Rejuvenate Bio last raise money?
Rejuvenate Bio's most recent round on record is a Series B, in Jun 2026.
What does Rejuvenate Bio do?
Rejuvenate Bio is a biotechnology company.
Where is Rejuvenate Bio headquartered?
Rejuvenate Bio is headquartered in San Diego, US.
Which VCs invest in companies like Rejuvenate Bio?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Rejuvenate Bio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Rejuvenate Bio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.